
Mechanistic Elucidation of Activation/Deactivation Signal Transduction within Neurotensin Receptor 1 Triggered by ‘Driver Chemical Groups’ of Modulators: A Comparative Molecular Dynamics Simulation

Xun Lu [#], Xinchao Shi [#], Jigang Fan, Mingyu Li, Yuxiang Zhang, [Shaoyong Lu](#) ^{*}, [Guanhuan Xu](#) ^{*}, [Ziqiang Chen](#) ^{*}

Posted Date: 30 June 2023

doi: 10.20944/preprints202306.2214.v1

Keywords: Neurotensin receptor 1; molecular dynamic simulation; signal transduction; selective interaction



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Mechanistic Elucidation of Activation/Deactivation Signal Transduction within Neurotensin Receptor 1 Triggered by 'Driver Chemical Groups' of Modulators: A Comparative Molecular Dynamics Simulation

Xun Lu ^{1,‡}, Xinchao Shi ^{1,‡}, Jigang Fan ¹, Mingyu Li ¹, Yuxiang Zhang ¹, Shaoyong Lu ^{1,*},
Guanhuan Xu ^{2,*} and Ziqiang Chen ^{3,*}

¹ Medicinal Chemistry and Bioinformatics Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

² Department of VIP Clinic, Changhai Hospital, Affiliated to Navy Medical University, Shanghai 200433, China

³ Department of Orthopedics, Changhai Hospital, Affiliated to Naval Medical University, Shanghai 200433, China

These authors contributed equally to this work.

* Correspondence: lushaoyong@sjtu.edu.cn (S.L.); 13621630676@163.com (G.X.); ziqiang_chensuper81@vip.163.com (Z.C.)

Abstract: Small molecule modulators of neurotensin receptor 1 (NTSR1), a class A G protein-coupled receptor (GPCR), has been emerging as promising therapeutics for psychiatric disorders and cancer. Interestingly, a chemical group substitution of NTSR1 modulators can launch different downstream regulation, highlighting the significance of deciphering the internal fine-tuning mechanism. Here, we conducted synergistic application of Gaussian accelerated molecular dynamics simulation, conventional molecular dynamics simulation, and Markov state models (MSM) to investigate the underpinning mechanism of 'driver chemical groups' of modulators triggering inverse signaling. The result indicated that the flexibility of leucine moiety in NTSR1 agonists contributes to the inward displacement of TM7 through a loosely coupled allosteric pathway, while the rigidity of adamantane moiety in NTSR1 antagonists leads to unfavorable downward transduction of agonistic signaling. Furthermore, we found that R322^{6.54}, Y319^{6.51}, F353^{7.42}, R148^{3.32}, S356^{7.45} and S357^{7.46} may play a key role in inducing the activation of NTSR1. Together, our findings not only highlight the ingenious signal transduction within class A GPCRs, but also lay a foundation for the development of targeted drugs harboring different regulatory function of NTSR1.

Keywords: neurotensin receptor 1; molecular dynamic simulation; signal transduction; selective interaction

1. Introduction

G protein-coupled receptors (GPCRs) are the most abundant types of receptors on eukaryotic cell membranes. Each of them typically contains a conserved architecture of seven transmembrane helices (TMs) that divide the receptor into N-terminus, C-terminus, three extracellular loops (ECLs), and three intracellular loops (ICLs) [1]. Once anchored by specific ligands, the receptor is activated through conformational rearrangements, followed by recruiting corresponding G proteins or β -arrestins to the intracellular binding site and triggering downstream signaling [2].

Neurotensin receptor 1 (NTSR1), a prototypical class A GPCR, plays a prominent role in central nervous system and in the periphery [3]. In the past 40 years, researchers have extensively developed small molecules and peptides to explore its biological functions [4–9]. These modulators, according to their biological effect, can be categorized into full agonists, partial agonists and antagonists [10]. Further studies have shown that NTSR1 agonists play an anti-addictive role in the central nervous

system, while antagonists inhibit the invasion and migration of peripheral cells, demonstrating the potential to treat a variety of peripheral tumors [3].

Among modulators, a ubiquitous phenomenon is that merely the substitution of adamantane into leucine moiety reverses antagonists into full agonists [6] (Figure 1). Mechanistic study of this phenomenon will be conducive to resolving fine-tuning signal regulation within class A GPCRs and accelerating the design of NTSR1 agonists or antagonists.




Figure 1. Graphic abstract of one 'driver chemical group' triggering inverse downstream signaling. (A) The abridged general view of NTSR1 antagonist SR48692 and full agonist ML301 inducing activation/deactivation signal transduction via the switch function of F353^{7.42}. (B) The structure and biological activity of SR48692 and ML301.

Recently, the complexes of NTSR1 and its ligands have been determined by either crystal or cryo-electron microscopy (cryo-EM) methodology [11–15], laying solid underpinning for this research. However, these snapshots are intrinsically static and therefore not sufficient enough to represent the dynamics of conformational ensemble to explain differences in protein internal signaling. Molecular dynamics (MD) simulations, initiating from static crystallographic structures, simulates dynamical information on atomic level and conformational transitions, serving as a crucial complementation for crystallography [16,17]. Its biophysical application ranges from protein conformational study [18,19], allosteric mechanisms [20,21], to drug discovery [22–25].

In view of conformational transition of GPCRs occurring over a large time scale, one of the enhanced sampling methodologies, Gaussian accelerated molecular dynamics (GaMD) simulation, is employed. GaMD adds a harmonic boost potential which follows a near-Gaussian distribution to smoothen the potential energy surface of the system, accelerating the transition between low-energy states [26]. With the advantage of no need to set predefined reaction coordinates and reducing the energetic noise, GaMD has witnessed extensive applications in GPCR conformational exploration [27,28].

Here, we selected representative NTSR1 agonist ML301 and antagonist SR48692 to decipher the mechanism of one-group difference triggering inverse NTSR1 signaling. GaMD (a total of 12 μ s) was performed as a pioneer to broaden the conformational landscape, while synergistic application of conventional MD (cMD) simulation (a total of 10.5 μ s) and Markov state models were conducted to characterize the detailed conformational dynamics of NTSR1 in different states. The result indicated that the flexibility distinction of leucine/adamantane moiety contributes to different signal transduction via a loosely coupled allosteric network. Furthermore, we found that R322^{6.54}, Y319^{6.51}, F353^{7.42}, S356^{7.45} and S357^{7.46} might play a constructive role in inducing the activation of NTSR1 receptor. Collectively, this research provides dynamic insights into the elaborate signaling pathway within NTSR1 and lays a promising foundation for refinement of modulators harboring different regulatory functions of NTSR1 receptor.

2. Materials and Methods

2.1. Construction of stimulated systems

Four model systems were built for MD simulations: inactive NTSR1+ML301 system, inactive NTSR1+SR48692 system, active NTSR1+ML301 system, active NTSR1+SR48692 system. The inactive NTSR1 structure was obtained by homology modeling based on corresponding murine structure (PDB ID: 6ZIN) [15]. SWISS-MODEL (<https://swissmodel.expasy.org/>) [29] and Pymol were utilized to remodel the truncated loops, carry out homology modeling and remove non-NTSR1 co-crystallized molecules. The obtained inactive state structure was then performed as receptor for molecular docking of ML301 and SR48692 utilizing Autodock Vina. The output ligand poses were carefully aligned, since adamantane versus leucine is the only major difference between the two compounds. Using the canonical state NTSR1 (PDB ID: 6OS9) [13] as the receptor, the active NTSR1+ML301 complex and the active NTSR1+SR48692 complex were constructed in a similar way. Then, the obtained complexes were oriented in the Orientations of Proteins in Membrane (OPM) server (opm.phar.umich.edu/) [30] and inserted into the POPC membrane in the CHARMM-GUI server [31]. Next, the systems were embedded in TIP3P water molecules with a length of 10 Å. The counterions concentration of 0.15 mol/L KCl were used to balance the system charge [32]. Finally, we used Amber-tleap program to generate the coordinate and topology files for simulation, with lipid 14 force field for POPC membrane [33], ff14SB force field for proteins [34], GAFF force field for ligands [35] and TIP3P model for water molecules [36].

2.2. Gaussian accelerated molecular dynamics (GaMD) simulations

The systems were first minimized with restraint of 500 kcal mol⁻¹Å⁻² on the NTSR1 receptors and ligands, while waters and counterions were minimized in 30,000 deepest descent cycles, followed by 20,000 conjugate gradient cycles. Second, all atoms were subjected to 4000 cycles of steepest descent and 20,000 cycles of conjugate gradient minimization without any restraint. Next, each system was gradually thermalized from 0 K to 310 K within 700 ps under isothermal-isovolumetric (NVT) conditions and finally equilibrated for 3.5 ns in an isothermal-isobaric (NPT) ensemble.

In the GaMD simulation method, when the system potential $V(\mathbf{r})$ is lower than the reference energy E at position \mathbf{r} , the updated $V^*(\mathbf{r})$ is calculated using Equations (1) and (2):

$$V^*(\vec{r}) = V(\vec{r}) + \Delta V(\vec{r}) \quad (1)$$

$$\Delta V(\vec{r}) = \begin{cases} \frac{1}{2}k(E - V(\vec{r}))^2, & V(\vec{r}) < E \\ 0, & V(\vec{r}) \geq E \end{cases} \quad (2)$$

where the two parameters E and k (the harmonic force constant) are automatically adjusted using Equations (3) and (4):

$$V_{\max} \leq E \leq V_{\min} + \frac{1}{k} \quad (3)$$

$$k = k_0 \frac{1}{V_{\max} - V_{\min}} \quad (4)$$

If E is set to the lower bound as V_{\max} , then k_0 can be calculated by Equation (5), while if E is set to the upper bound $E = V_{\min} + \frac{1}{k}$, then k_0 can be calculated by Equation (6):

$$k_0 = \min(1.0, \frac{\sigma_0}{\sigma_v} \times \frac{V_{\max} - V_{\min}}{V_{\max} - V_{\text{avg}}}) \quad (5)$$

$$k_0 = (1.0 - \frac{\sigma_0}{\sigma_v}) \times \frac{V_{\max} - V_{\min}}{V_{\text{avg}} - V_{\min}} \quad (6)$$

where V_{\max} , V_{\min} and V_{avg} denote the maximum, minimum and averaged potential energy of simulated systems, with σ_v and σ_0 refer to the standard deviation of potential energy and user-specified upper limit for proper reweighting, respectively.

To conduct GaMD product simulation, conventional MD simulation of 100 ns was first performed to obtain V_{\max} , V_{\min} , V_{avg} , σ_v and the greatest σ_0 and k_0 . Next, 60 ns GaMD equilibration were conducted to collect boost potential [27]. Last, four systems underwent 3 rounds of 1 μ s dual-boost GaMD simulations with random velocities and an integration step of 2.0 fs. During simulations, the particle mesh Ewald (PME) method was employed to evaluate the long-range electrostatic interactions while a cutoff of 10 Å was used for short-range electrostatic and van der Waals interactions [37]. Covalent bonds involving hydrogen were restricted using the SHAKE algorithm [38]. The temperature of the systems was kept at 310 K using the Langevin dynamics with the coupling time constant of 1.0 ps. The coordinates of the snapshots were collected every 200 ps.

2.3. Conventional molecular dynamics (cMD) simulations

To reasonably select replicas in GaMD simulations, K-means clustering algorithm was performed and finally two replicas of the active NTSR1+ML301 system and five replicas of the active NTSR1+SR48692 system were selected. The restart files were extracted according to the representative frames for the input of cMD simulation. Then, seven systems underwent 3 rounds of 500 ns cMD simulations with random velocities and an integration step of 2.0 fs. The simulation settings and methods kept consistent with GaMD simulations except for removing the boost potential.

2.4. Dynamic Cross-Correlation Matrix (DCCM) analysis

The Dynamic Cross-Correlation Matrix (DCCM) analysis was performed using the CPPTRAJ module [39] of AMBER18 on representative trajectories to investigate the coupled motions between atoms. Based on the normalized cross-correlation matrix C , the 'Pearson-like' cross-correlation coefficient (ρ) is calculated using Equation (7):

$$C_{ij} = \frac{\langle (r_i - \langle r_i \rangle) \cdot (r_j - \langle r_j \rangle) \rangle}{\sqrt{\langle (r_i - \langle r_i \rangle)^2 \rangle \cdot \langle (r_j - \langle r_j \rangle)^2 \rangle}} \quad (7)$$

where r_i and r_j indicate the position vectors of i th and j th atoms.

2.5. Principal component analysis (PCA) and free energy landscape (FEL)

To capture the dominant motions during simulation, an effective statistical method PCA was introduced by constructing covariance matrix, diagonalizing the matrix to generate eigenvectors and computing eigenvalues based on the mean square fluctuation of trajectories projected along the eigenvectors. The eigenvectors, interpreted as principal components, were ranked by eigenvalues, with the top-ranked eigenvectors (such as PC1 and PC2) represent the most influential dynamics of the system [40].

$$G_i = -k_B T \ln\left(\frac{N_i}{N_m}\right) \quad (8)$$

where k_B , T , N_i and N_m represent Boltzmann constant, simulation temperature, the population of i th bin and the population of most populated bins. To enhance the diversity of indicator selection to ensure comprehensive conformational depiction, we selected indicators including distance, angle and RMSD values.

2.6. Community network analysis (CNA)

Benefited from correlation coefficient matrix C_{ij} and the NetworkView plugin in VMD, we computed the community organization distinction between the active NTSR1+ML301 system and the active NTSR1+SR48692 system. In this analysis, each C_α atom was recognized as a node. Based on Equation (7), the edge connections between nodes can be further calculated using Equation (11):

$$d_{i,j} = -\log(|C_{i,j}|) \quad (11)$$

where C_{ij} was computed using Equation (7) with i and j represent two nodes here. Two nodes are considered connected with a cutoff distance of 4.5 Å for at least 75% of the simulation time. Next, connected substructures, namely 'communities', was generated utilizing Girvan–Newman algorithm with a cutoff residue number of 3. The edge betweenness, put as the number of optimal paths travel across certain edge, was then calculated and set proportional to the width of bonds bridging communities [42,43].

2.7. Markov state models (MSM) construction and validation

Harnessing activation/deactivation parameters as input, Markov state models (MSM) was constructed following the standard PyEMMA protocol (<http://www.emma-project.org/latest/>) [44]. First, both the active NTSR1+ML301 system and the active NTSR1+SR48692 system was validated Markovian through the implied timescale (ITS) verification obeying Equation (12):

$$t_i = \frac{-\tau}{\ln|\lambda_i(\tau)|} \quad (12)$$

where τ represents the lag time and λ_i denotes the eigenvalues of the Markov transition matrix.

Then, the free-energy landscape was decomposed into 120 microstates using K-means clustering algorithm and MSMs was established with an ITS-unaffected lag time of 5 ns. Thereupon, the Perron Cluster Analysis (PCCA+) algorithm was assigned to converge the microstates into four metastates, where Chapman–Kolmogorov test was subsequently conducted to validate Markovian among them. Next, the transition path theory (TPT) was applied to calculate the mean first passage time (MFPT) for activation/deactivation process based on the transition probability matrix of MSMs. Finally, utilizing MDTraj package, we extracted the structures near the microstate cluster centers of corresponding metastate into new trajectories and selected the representative conformation of each metastate according to the similarity score S_{ij} given by Equation (13):

$$S_{ij} = e^{-d_{ij}/d_{scale}} \quad (9)$$

where d_{ij} is the RMSD between conformation i and j , while d_{scale} is the standard deviation of d .

3. Results

3.1. Antagonist SR48692 and agonist ML301 binding induce respective inactive and active conformations of NTSR1

To comprehensively explore the conformational landscape, each 1 μ s \times 3 rounds of GaMD simulations was performed on four systems, including the inactive NTSR1+SR48692 system, the inactive NTSR1+ML301 system, the active NTSR1+SR48692 system, and the active NTSR1+ML301 system. We defined two parameters (namely collective variables, CVs) to project the simulated trajectories onto a two-dimensional (2D) space, to depict the global conformational transition during NTSR1 activation/deactivation. Since the most quintessential feature shared by class A GPCRs activation is the outward movements of TM5 and TM6 and the inward displacement of TM7 at the

intracellular side [19,20,32], the first CV is the distance between the center of mass of S253^{5.55} (superscripts indicate the Ballesteros-Weinstein numbering for GPCR residues) in TM5 and S356^{7.45}-S357^{7.46} in TM7 (distance TM5-TM7). The decrease of TM5-TM7 distance represents the inward movement of TM7. The distance between the center of mass of Y103^{2.41} in TM2 and V302^{6.34} in TM6 (distance TM2-TM6) is defined as the second CV. The increase of TM2-TM6 distance means the outward displacement of TM6.

Antagonist SR48692 and agonist ML301 binding induces distinct conformational ensemble of NTSR1 (Figure 2). Since the initial inactive structure is characterized by a TM5-TM7 distance of 22.45 Å and a TM2-TM6 distance of 14.42 Å, the density basin with a TM5-TM7 distance of ~20-23 Å and a TM2-TM6 distance of ~14-15 Å represents the inactive state (Figure 2A and 2B). Similarly, with the initial active structure featuring a TM5-TM7 distance of 16.86 Å and a TM2-TM6 distance of 24.35 Å, the active conformation can be characterized by the density basin with a TM5-TM7 distance of ~16.5-19 Å and a TM2-TM6 distance of ~20.5-25 Å (Figure 2C and 2D). These observations suggest that the active conformations are inaccessible initiating from the inactive state of NTSR1 due to high energy barrier even with agonist ML301 binding (Figure 2A and 2B), while the inactive conformations are captured initiating from the active state of NTSR1 in the presence of antagonist SR48692 (Figure 2C and 2D). Once bound to SR48692, the receptor transits from the active into inactive states through several intermediate conformations (Figure 2C). In contrast, the full agonist ML301 binding stabilizes the receptor in the active state (Figure 2D). 2D landscape projected by other parameters (CV1: TM3-TM6 distance, evaluated by the distance between the center of mass of R166^{3.50} in TM3 and V302^{6.34} in TM6; CV2: NPxxY RMSD, evaluated by root mean square deviation of non-symmetric side-chain atoms of residues N360^{7.49} to Y364^{7.53}) demonstrates similar results (Figure S1).




Figure 2. The free energy landscapes of the inactive NTSR1+SR48692 system (A), the inactive NTSR1+ML301 system (B), the active NTSR1+SR48692 system (C) and the active NTSR1+ML301

system (D) are shown by simulation trajectory projection. Collective variable 1 (CV1): TM5-TM7 distance, CV2: TM2-TM6 distance. Color scale on the right is evaluated through density. The red stars denote the positions of representative structures extracted using K-means clustering.

We used K-means clustering to extract five representative conformations from GaMD trajectories of the active NTSR1+SR48692 system (Figure 2C) and two representative conformations from GaMD trajectories of the active NTSR1+ML301 system (Figure 2D), and then performed additional 500 ns \times 3 rounds cMD simulations on the seven systems with each extracted conformation as the initial structure. The RMSD value of ligands in all simulations was first proved to reach convergence in both systems (Figure S2A), in order to verify the rationality of our docking and simulation. Then, the free energy landscape was depicted using identical CVs. Antagonist SR48692 binding induces the gradual deactivation of NTSR1 through a transition pathway of M1 (the active state, 30.4%) \rightarrow M2 (the intermediate state, 20.1%) \rightarrow M3 (the intermediate state, 8.4%) \rightarrow M4 (the inactive state, 38.7%) (Figure 3A). Significantly, the representative conformation extracted from each energy basin features typical characteristics of the active state, the intermediate state and the inactive state, as revealed by the conformational arrangements of TM5, TM6 and TM7 (Figure 3B). Porcupine plot was constructed to graphically visualize the dominant movements of different regions (Figure S2B). The outward shifts of TM5 and TM6 and the inward translocation of TM7 present the dominant conformational dynamics despite the highly flexible loops. In contrast, agonist ML301 binding stabilizes NTSR1 in the active state (Figure 3C). 2D landscape projected by TM3-TM6 distance (CV1) and NPxxY RMSD (CV2) illustrates similar results (Figure S2C and S2D).

We further applied Markov state models to unveil the transition detail of the active NTSR1+SR48692 system (Figure 3D). The result indicates that the M1 \rightarrow M2 (20.8 μ s) and M2 \rightarrow M3 (79.2 μ s) transition times are shorter than the corresponding reverse processes (38.8 and 130.0 μ s, respectively), which confirm that the inactive state is more accessible than the active state with the binding of SR48692 to the active NTSR1. Notably, owing to the lowest population of the M3 state, a long timescale is required for the complete deactivation of the receptor, implying that NTSR1 deactivation is a slow motion.




Figure 3. The free energy landscapes of the active NTSR1+SR48692 system (A) and the active NTSR1+ML301 system (C) in cMD simulation. The unit of free energy values is kcal/mol. Color scale on the right is evaluated through free energy. (B) The representative conformations of the active NTSR1+SR48692 system in cMD simulation. Active state, tangerine; intermediate state, cyan; inactive state, green. (D) The transition timescale among representative conformations of the active NTSR1+SR48692 system, represented by the mean first passage time.

3.2. Agonist ML301 binding contributes to enhanced conformational dynamics

To reveal the dynamic movement of protein domains within the receptor, we conducted dynamic cross-correlation matrix analysis using trajectories of representative conformations. In the active NTSR1+SR48692 system, less correlations were observed in the active (Figure 4A), intermediate (Figure 4B), and inactive (Figure 4C) states. In contrast, the enhanced movements were observed in the active NTSR1+ML301 system (Figure 4D), thus altering the protein internal structure for enhanced signal propagation, which may promote activation signal transduction.

The atomic root-mean square fluctuations (RMSFs) of $C\alpha$ atoms around their original positions were subsequently quantified for each residue to compare the mobility of different regions (Figure 4E). Major fluctuated functional regions in the two systems include TM5, TM6 and extracellular TM7. Due to the deactivation of the receptor, TM5 and TM6 of the active NTSR1+SR48692 system display remarkable inward movement and therefore fluctuate more frequently than that of the active NTSR1+ML301 system. Notably, in the active NTSR1+ML301 system, the extracellular region of TM7 experiences more fluctuation than that of the active NTSR1+SR48692 system. Because the extracellular TM7 approaches to the ligand binding site, the residues within this region might function as a trigger for discriminating the activation or deactivation signal.




Figure 4. The dynamic cross-correlation matrix analysis of the active NTSR1+SR48692 system (active state) (A), the active NTSR1+SR48692 system (intermediate state) (B), the active NTSR1+SR48692 system (inactive state) (C), and the active NTSR1+ML301 system (D). Color scales are shown on the right. The interactions whose absolute correlation coefficients are less than 0.3 are colored white for clarity. (E) The RMSF analysis of the active NTSR1+SR48692 system (pink curve) and the active NTSR1+ML301 system (blue curve).

3.3. The flexibility of leucine moiety in agonist ML301 contributes to the inward displacement of TM7

The intramolecular interactions, including hydrogen bonds, salt bridges, polar interactions, and hydrophobic interactions, play critical roles in signal propagation within the protein [45]. To uncover distinct signal transduction, we analyzed different kinds of interactions of the active NTSR1+SR48692 system and the active NTSR1+ML301 system based on the representative trajectories. Here, proportional chord diagrams were used to describe the specific interactions that occupies over 50% of the simulation time (Figure 5).




Figure 5. The specific interactions within the active NTSR1+SR48692 system (A) and the active NTSR1+ML301 system (B) revealed by proportional chord diagram. The chords connecting two residues denote specific interactions that occupies over 50% of the simulation time.

Proximal to the ligand binding site, F353^{7.42} forms π - π stacking with Y319^{6.51} in the active NTSR1+SR48692 system (Figure 5A). In contrast, it forms selective π -cation interaction with R148^{3.32} in the active NTSR1+ML301 system (Figure 5B). During simulations, we found that the adamantane moiety of antagonist SR48692 exhibits relative rigidity with less fluctuation (RMSF: 1.13 Å). The salt bridge between ligand's carboxyl group and R322^{6.54}, the π -cation interaction between R322^{6.54} and Y319^{6.51}, and the π - π stacking between Y319^{6.51} and F353^{7.42}, are stable, in which case the orientation of F353^{7.42} hinders its interaction with R148^{3.32} (Figure 6A-C). However, the leucine moiety of agonist ML301 experiences more fluctuation (RMSF: 1.22 Å) due to its flexibility, which can interact with Y319^{6.51} through the stable interaction of carboxyl group-R322^{6.54}-Y319^{6.51}. The vibration of Y319^{6.51} results in the breakage of its π - π stacking with F353^{7.42} (Figure 6D), thus driving F353^{7.42} to form π -cation interaction with R148^{3.32} by forwarding 1.6 Å and rotating 36.6° (Figure 7A). Collectively, the flexibility of leucine moiety in agonist ML301 contributes to selective π -cation interaction between F353^{7.42} and R148^{3.32}, which deciphers the first level of signal transduction.




Figure 6. The interaction analysis of the active NTSR1+SR48692 system (active state) (A), the active NTSR1+SR48692 system (intermediate state) (B), the active NTSR1+SR48692 system (inactive state) (C) and the active NTSR1+ML301 system (D). Y319^{6.51}-F353^{7.42}-R148^{3.32} interactions are zoomed for clarity.

In the second level of allosteric signaling, owing to the reorientation of F353^{7.42}, the hydrogen bond preference for S356^{7.45}/S357^{7.46} is reshaped. In the active NTSR1+SR48692 system, the length of hydrogen bond between F353^{7.42} and S357^{7.46} is shorter than that between F353^{7.42} and S356^{7.45}, resulting in a preference for hydrogen bond formation between F353^{7.42} and S357^{7.46} (Figure 7B-D). In contrast, in the active NTSR1+ML301 system, the right rotation of the aromatic ring reacts the left rotation of oxygen atom of F353^{7.42}. As a result, the hydrogen bond preference experiences a transition from S357^{7.46} to S356^{7.45} (Figure 7E). Whereas S356^{7.45} and S357^{7.46} is located at the inward and outward regions of TM7, respectively, the transition of hydrogen bond preference ultimately results in rigidity release in the outward region of TM7 and thus urges its inward displacement. The displacement of TM7, a typical feature of class A GPCR activation, has a high potential to stabilize NTSR1 active conformation, which elucidates the agonistic activity of agonist ML301. Similarly, the hydrogen bond preference between F353^{7.42} and S357^{7.46} resulting from the adamantane moiety of antagonist SR48692 hinders the transduction of activation signals, in which case NTSR1 adheres to the intrinsic deactivation process of class A GPCRs [46].




Figure 7. (A) The residue superimposed analysis of the active NTSR1+SR48692 system (active state) (tangerine) and the active NTSR1+ML301 system (wheat). The preference for hydrogen bonds among F353^{7.42}-S356^{7.45}/S357^{7.46} in the active NTSR1+SR48692 system (active state) (B), the active NTSR1+SR48692 system (intermediate state) (C), the active NTSR1+SR48692 system (inactive state) (D), and the active NTSR1+ML301 system (E).

3.4. Community networks indicate preference for activation signal transduction originating from R148^{3.32}

The propagation of allosteric signals within NTSR1 was further explored using community network analysis, to investigate the variational coupling among all communities. During the trajectory, residues within a cutoff distance of 4.5 Å for at least 75% of the simulation time were classified as part of the same communities, which were recognized as synergistic functional units within the overall protein. The visualized community network graphs provide clear depictions of the allosteric crosstalk paths and the corresponding intensities within NTSR1 in different systems (Figure 8).




Figure 8. The community network analysis of the active NTSR1+SR48692 system (A) and the active NTSR1+ML301 system (B). Each sphere represents a corresponding community whose number of residue components is indicated with the sphere area. While the sticks connecting different spheres visualize the inter-community connections, and the thickness of these sticks is proportional to the value of edge connectivity.

Distinct alterations in the topological characteristics and the intercommunity communications within NTSR1 allosteric network were observed with the binding of SR48692 and ML301. In the active NTSR1+SR48692 system, the residues that engage in the first level of signal transduction involve in Community 4, which shares relatively weak and indirect interaction with Communities 2, 7, and 9 within the position of intracellular TM5, TM6 and TM7 (Figure 8A). It is therefore hypothesized that such weak correlation contributes to unfavorable downstream transduction of activation signals, in which case NTSR1 will exhibit a slow deactivation trend. However, in the active NTSR1+ML301 system, R148^{3,32}, which forms selective π -cation interaction with F353^{7,42}, belongs to a sub-community 4", which forms relatively strong interaction with Communities 2 and 7 (at the position of intracellular TM5, TM6 and TM7) mediated by Community 3 (Figure 8B). In view of this, it is implied that activation signals have more tendency to be transmitted to the intracellular TM5, TM6 and TM7.

Moreover, helix 8 of the active NTSR1+SR48692 system belongs to Community 7' independent of Community 7, in which case gradual elimination of membrane localization of helix8, a canonical feature of class A GPCR deactivation, is more achievable (Figure 8A). Comparatively, in the active NTSR1+ML301 system, helix8 and TM7 jointly constitute Community 7, indicating the collaborative movement of the two domains and therefore the stability of helix8 membrane localization and the active conformation (Figure 8B).

4. Discussion

GPCRs are versatile cellular sensors for chemical stimulus, serving as promising targets for about 30% of approved drugs [47]. The prototypical class A GPCR NTSR1 exerts dual activity both in the central nervous system and in the periphery, demonstrating brilliant therapeutic prospect. However, even with its crystallographic complex with G-proteins and β -arrestins, the activation or deactivation regulation pathway with the receptor has not been explicitly decoded, leaving blindness for drug discovery. Herein, to unravel the possible signal pathways within the receptor, we focus on a ubiquitous phenomenon, where one single moiety difference in NTSR1 modulators can evoke distinct agonistic and antagonistic downstream signaling. In order to elucidate the underpinning mechanism, we performed 12 μ s GaMD simulation to broaden the conformational landscape, followed by 10.5 μ s cMD simulation to capture the dynamics of activation/deactivation signal transduction and Markov state models to investigate the conformational transition timescale.

The free energy landscape revealed that antagonist and agonist induce inactive and active conformation over an extensive timescale, respectively, with representative conformations extracted from the energy basin showing canonical features of receptor activation/deactivation through the displacement of TM5, TM6 and TM7. DCCM analysis indicated that the full agonist ML301 stimulates NTSR1 internal structure to be more dynamic for activation signal propagation. Comparative RMSF data showed that extracellular TM7 may serve as the initiating region for discriminating the activation or deactivation signal. By stepwise dynamics exploration, we uncovered that flexibility of leucine indirectly accounts for selective π -cation interaction between F353^{7,42} and R148^{3,32}, inducing the reorientation of F353^{7,42} and thus reshaping the hydrogen bond preference for S356^{7,45}/S357^{7,46}. It is implied that the hydrogen bond preference for S356^{7,45} subsequently results in outward rigidity release and inward bending of TM7, thus contributing to the stability of the active conformation. Comparatively, the rigidity of adamantane moiety in the antagonist indirectly leads to the hydrogen bond preference between F353^{7,42} and S357^{7,46}, failing to block the intrinsic gradual deactivation process of class A GPCR. Such a loosely coupled allosteric network, comprising two main stages for signal transduction, links small perturbations at the extracellular ligand binding site to large conformational changes at the intracellular G-protein-binding site, explaining the cause of reverse

biological effect inducing by two modulators. Furthermore, R322^{6.54}, Y319^{6.51}, F353^{7.42}, R148^{3.32}, S356^{7.45} and S357^{7.46}, in which F353^{7.42} functions as a junction switch, may play a constructive role in NTSR1 activation. Finally, to graphically overview the signal propagation towards other regions apart from TM7, we conducted comparative community network analysis and found that the sub-community formed in the active NTSR1+ML301 network creates a favorable condition for signal transduction towards TM5, TM6 and TM7, which enhances the activation signaling to tackle the deactivation process. Taken together, our comparative MD simulations provide a mechanistic elucidation of one single moiety difference in ligands triggering inverse NTSR1 signaling.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Figure S1: The analogical free energy landscape of the inactive NTSR1+ML301 system (A), the inactive NTSR1+SR48692 system (B), the active NTSR1+SR48692 system (C) and the active NTSR1+ML301 system (D) in GaMD simulation (CV1: TM3-TM6 distance, CV2: NPxxY RMSD); Figure S2: The free energy landscape of the active NTSR1+SR48692 system (A) and the active NTSR1+ML301 system (B) in cMD simulation (CV1: TM3-TM6 distance, CV2: NPxxY RMSD), (C) The RMSD value of ligands in all simulations in the active NTSR1+SR48692 system and the active NTSR1+ML301 system, (D) The principal pattern of motion of the active NTSR1+SR48692 system; Figure S3: Implied timescale test for MSMs in the active NTSR1+SR48692 system (A) and the active NTSR1+ML301 system (C) at different lag times and Chapman-Kolmogorov test of metastable states for the active NTSR1+SR48692 system (B) and the active NTSR1+ML301 system (D). Table S1: Frequency of Y319^{6.51}-F353^{7.42} and F353^{7.42}-R148^{3.32} interaction in the representative trajectories in the active NTSR1+SR48692 system and the active NTSR1+ML301 system.

Author Contributions: Conceptualization, S.L., G.X., Z.C.; methodology and validation, X.L., X.S., J.F., M.L. and Y.Z.; formal analysis, investigation and data curation, X.L., X.S.; resources, S.L.; writing—original draft preparation, X.L.; writing—review and editing, S.L.; visualization, X.L. and X.S., supervision, S.L., G.X., Z.C.; project administration, S.L.; funding acquisition, Z.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Innovative Research Team of High-Level Local Universities in Shanghai.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Venkatakrishnan, A.; Deupi, X.; Lebon, G.; Tate, C.G.; Schertler, G.F.; Babu, M.M. Molecular signatures of G-protein-coupled receptors. *Nature* 2013, 494, 185-194.
2. Flock, T.; Ravarani, C.N.; Sun, D.; Venkatakrishnan, A.J.; Kayikci, M.; Tate, C.G.; Veprintsev, D.B.; Babu, M.M. Universal allosteric mechanism for G α activation by GPCRs. *Nature* 2015, 524, 173-179.
3. Wu, Z.; Martinez-Fong, D.; Trédaniel, J.; Forgez, P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. *Frontiers in endocrinology* 2013, 3, 184.
4. Gully, D.; Labeeuw, B.; Boigegrain, R.; Oury-Donat, F.; Bachy, A.; Poncelet, M.; Steinberg, R.; Suaud-Chagny, M.F.; Santucci, V.; Vita, N. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. *Journal of Pharmacology and Experimental Therapeutics* 1997, 280, 802-812.
5. Fan, Y.; Lai, M.H.; Sullivan, K.; Popiolek, M.; Andree, T.H.; Dollings, P.; Pausch, M.H. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. *Bioorganic & medicinal chemistry letters* 2008, 18, 5789-5791.
6. Thomas, J.B.; Navarro, H.; Warner, K.R.; Gilmour, B. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay. *Bioorganic & medicinal chemistry letters* 2009, 19, 1438-1441.

7. Peddibhotla, S.; Hedrick, M.P.; Hershberger, P.; Maloney, P.R.; Li, Y.; Milewski, M.; Gosalia, P.; Gray, W.; Mehta, A.; Sugarman, E. Discovery of ML314, a brain penetrant nonpeptidic β -arrestin biased agonist of the neurotensin NTR1 receptor. *ACS medicinal chemistry letters* 2013, 4, 846-851.
8. Hershberger, P.M.; Hedrick, M.P.; Peddibhotla, S.; Mangravita-Novo, A.; Gosalia, P.; Li, Y.; Gray, W.; Vicchiarelli, M.; Smith, L.H.; Chung, T.D. Imidazole-derived agonists for the neurotensin 1 receptor. *Bioorganic & medicinal chemistry letters* 2014, 24, 262-267.
9. Slosky, L.M.; Bai, Y.; Toth, K.; Ray, C.; Rochelle, L.K.; Badea, A.; Chandrasekhar, R.; Pogorelov, V.M.; Abraham, D.M.; Atluri, N. β -arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors. *Cell* 2020, 181, 1364-1379. e1314.
10. Di Fruscia, P.; He, Y.; Koenig, M.; Tabrizifard, S.; Nieto, A.; McDonald, P.H.; Kamenecka, T.M. The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1). *Bioorganic & medicinal chemistry letters* 2014, 24, 3974-3978.
11. Robertson, M.J.; Papisergi-Scott, M.M.; He, F.; Seven, A.B.; Meyerowitz, J.G.; Panova, O.; Peroto, M.C.; Che, T.; Skiniotis, G. Structure determination of inactive-state GPCRs with a universal nanobody. *Nature Structural & Molecular Biology* 2022, 1-8.
12. Yin, W.; Li, Z.; Jin, M.; Yin, Y.-L.; De Waal, P.W.; Pal, K.; Yin, Y.; Gao, X.; He, Y.; Gao, J. A complex structure of arrestin-2 bound to a G protein-coupled receptor. *Cell research* 2019, 29, 971-983.
13. Kato, H.E.; Zhang, Y.; Hu, H.; Suomivuori, C.-M.; Kadji, F.M.N.; Aoki, J.; Krishna Kumar, K.; Fonseca, R.; Hilger, D.; Huang, W. Conformational transitions of a neurotensin receptor 1-Gi1 complex. *Nature* 2019, 572, 80-85.
14. Huang, W.; Masureel, M.; Qu, Q.; Janetzko, J.; Inoue, A.; Kato, H.E.; Robertson, M.J.; Nguyen, K.C.; Glenn, J.S.; Skiniotis, G. Structure of the neurotensin receptor 1 in complex with β -arrestin 1. *Nature* 2020, 579, 303-308.
15. Deluigi, M.; Klipp, A.; Klenk, C.; Merklinger, L.; Eberle, S.A.; Morstein, L.; Heine, P.; Mittl, P.R.; Ernst, P.; Kamenecka, T.M. Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism. *Science Advances* 2021, 7, eabe5504.
16. Hansson, T.; Oostenbrink, C.; van Gunsteren, W. Molecular dynamics simulations. *Current opinion in structural biology* 2002, 12, 190-196.
17. Klepeis, J.L.; Lindorff-Larsen, K.; Dror, R.O.; Shaw, D.E. Long-timescale molecular dynamics simulations of protein structure and function. *Current opinion in structural biology* 2009, 19, 120-127.
18. Byun, J.A.; VanSchouwen, B.; Akimoto, M.; Melacini, G. Allosteric inhibition explained through conformational ensembles sampling distinct "mixed" states. *Computational and Structural Biotechnology Journal* 2020, 18, 3803-3818.
19. Wang, Y.; Li, M.; Liang, W.; Shi, X.; Fan, J.; Kong, R.; Liu, Y.; Zhang, J.; Chen, T.; Lu, S. Delineating the activation mechanism and conformational landscape of a class BG protein-coupled receptor glucagon receptor. *Computational and Structural Biotechnology Journal* 2022, 20, 628-639.
20. Zhang, H.; Chu, G.; Wang, G.; Yao, M.; Lu, S.; Chen, T. Mechanistic Understanding of the Palmitoylation of Go Protein in the Allosteric Regulation of Adhesion Receptor GPR97. *Pharmaceutics* 2022, 14, 1856.
21. Marasco, M.; Kirkpatrick, J.; Nanna, V.; Sikorska, J.; Carlomagno, T. Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network. *Computational and Structural Biotechnology Journal* 2021, 19, 2398-2415.
22. Lu, S.; Chen, Y.; Wei, J.; Zhao, M.; Ni, D.; He, X.; Zhang, J. Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators. *Acta Pharmaceutica Sinica B* 2021, 11, 1355-1361.
23. Qiu, Y.; Yin, X.; Li, X.; Wang, Y.; Fu, Q.; Huang, R.; Lu, S. Untangling dual-targeting therapeutic mechanism of epidermal growth factor receptor (EGFR) based on reversed allosteric communication. *Pharmaceutics* 2021, 13, 747.
24. Lu, S.; Qiu, Y.; Ni, D.; He, X.; Pu, J.; Zhang, J. Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery. *Drug discovery today* 2020, 25, 177-184.
25. Ni, D.; Li, X.; He, X.; Zhang, H.; Zhang, J.; Lu, S. Drugging K-RasG12C through covalent inhibitors: mission possible? *Pharmacology & therapeutics* 2019, 202, 1-17.
26. Wang, J.; Arantes, P.R.; Bhattarai, A.; Hsu, R.V.; Pawnikar, S.; Huang, Y.m.M.; Palermo, G.; Miao, Y. Gaussian accelerated molecular dynamics: Principles and applications. *Wiley Interdisciplinary Reviews: Computational Molecular Science* 2021, 11, e1521.

27. Miao, Y.; McCammon, J.A. Graded activation and free energy landscapes of a muscarinic G-protein-coupled receptor. *Proceedings of the National Academy of Sciences* 2016, 113, 12162-12167.
28. Miao, Y.; McCammon, J.A. Mechanism of the G-protein mimetic nanobody binding to a muscarinic G-protein-coupled receptor. *Proceedings of the National Academy of Sciences* 2018, 115, 3036-3041.
29. Waterhouse, A.; Bertoni, M.; Bienert, S.; Studer, G.; Tauriello, G.; Gumienny, R.; Heer, F.T.; de Beer, T.A.P.; Rempfer, C.; Bordoli, L. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic acids research* 2018, 46, W296-W303.
30. Lomize, M.A.; Lomize, A.L.; Pogozheva, I.D.; Mosberg, H.I. OPM: orientations of proteins in membranes database. *Bioinformatics* 2006, 22, 623-625.
31. Lee, J.; Cheng, X.; Swails, J.M.; Yeom, M.S.; Eastman, P.K.; Lemkul, J.A.; Wei, S.; Buckner, J.; Jeong, J.C.; Qi, Y. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. *Journal of chemical theory and computation* 2016, 12, 405-413.
32. Lu, S.; He, X.; Yang, Z.; Chai, Z.; Zhou, S.; Wang, J.; Rehman, A.U.; Ni, D.; Pu, J.; Sun, J. Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design. *Nature Communications* 2021, 12, 4721.
33. Dickson, C.J.; Madej, B.D.; Skjevik, Å.A.; Betz, R.M.; Teigen, K.; Gould, I.R.; Walker, R.C. Lipid14: the amber lipid force field. *Journal of chemical theory and computation* 2014, 10, 865-879.
34. Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. *Journal of chemical theory and computation* 2015, 11, 3696-3713.
35. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. *Journal of computational chemistry* 2004, 25, 1157-1174.
36. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential functions for simulating liquid water. *The Journal of chemical physics* 1983, 79, 926-935.
37. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An $N \cdot \log(N)$ method for Ewald sums in large systems. *The Journal of chemical physics* 1993, 98, 10089-10092.
38. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H.J. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *Journal of computational physics* 1977, 23, 327-341.
39. Roe, D.R.; Cheatham III, T.E. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. *Journal of chemical theory and computation* 2013, 9, 3084-3095.
40. Amadei, A.; Linssen, A.B.; Berendsen, H.J. Essential dynamics of proteins. *Proteins: Structure, Function, and Bioinformatics* 1993, 17, 412-425.
41. Zhou, R.; Berne, B.J.; Germain, R. The free energy landscape for β hairpin folding in explicit water. *Proceedings of the National Academy of Sciences* 2001, 98, 14931-14936.
42. Newman, M.E. Modularity and community structure in networks. *Proceedings of the national academy of sciences* 2006, 103, 8577-8582.
43. Sethi, A.; Eargle, J.; Black, A.A.; Luthey-Schulten, Z. Dynamical networks in tRNA: protein complexes. *Proceedings of the National Academy of Sciences* 2009, 106, 6620-6625.
44. Scherer, M.K.; Trendelkamp-Schroer, B.; Paul, F.; Pérez-Hernández, G.; Hoffmann, M.; Plattner, N.; Wehmeyer, C.; Prinz, J.-H.; Noé, F. PyEMMA 2: A software package for estimation, validation, and analysis of Markov models. *Journal of chemical theory and computation* 2015, 11, 5525-5542.
45. Chandel, T.I.; Zaman, M.; Khan, M.V.; Ali, M.; Rabbani, G.; Ishtikhar, M.; Khan, R.H. A mechanistic insight into protein-ligand interaction, folding, misfolding, aggregation and inhibition of protein aggregates: An overview. *International Journal of Biological Macromolecules* 2018, 106, 1115-1129.
46. Dror, R.O.; Arlow, D.H.; Maragakis, P.; Mildorf, T.J.; Pan, A.C.; Xu, H.; Borhani, D.W.; Shaw, D.E. Activation mechanism of the β 2-adrenergic receptor. *Proceedings of the National Academy of Sciences* 2011, 108, 18684-18689.
47. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schiöth, H.B.; Gloriam, D.E. Trends in GPCR drug discovery: new agents, targets and indications. *Nature reviews Drug discovery* 2017, 16, 829-842.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)

disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.